Amplia Therapeutics Limited (ATX.AX)
AUD 0.08
(-2.35%)
AUD 0.08
(-2.35%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -5.12 Million | -5.28 Million | -4.4 Million | -2.91 Million | -2.08 Million | -987.34 Thousand |
| Net Income | -4.5 Million | -6.24 Million | -3.64 Million | -2.28 Million | -2.21 Million | -1.86 Million |
| Depreciation & Amortization | 86.14 Thousand | 73.36 Thousand | 3209.00 | 672.00 | 801.00 | 1590.00 |
| Deferred income taxes | - | 313.78 Thousand | -889.08 Thousand | -1.34 Million | -279.32 Thousand | -647.98 Thousand |
| Stock-based compensation | 85.99 Thousand | 209.09 Thousand | 60.95 Thousand | 353.95 Thousand | 202.83 Thousand | 244.39 Thousand |
| Change in working capital | -796.01 Thousand | 669.61 Thousand | -821.71 Thousand | -989.85 Thousand | -74.88 Thousand | 403.58 Thousand |
| Other non-cash items | 1.05 Million | -313.11 Thousand | 888.83 Thousand | 1.34 Million | 282.06 Thousand | 881.02 Thousand |
| Investing Cash Flow | -2226.00 | -58.42 Thousand | -26.64 Thousand | -5347.00 | - | -3188.00 |
| Investments in PPE | -2226.00 | -17.63 Thousand | -14.4 Thousand | -5347.00 | - | -3188.00 |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | -40.79 Thousand | -12.24 Thousand | - | - | - |
| Financing Cash Flow | -772.98 Thousand | -84.21 Thousand | 17.18 Million | 3.66 Million | 1.95 Million | -12.14 Thousand |
| Debt repayment | -633 Thousand | -64.64 Thousand | -2.1 Million | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | -1.18 Million | -400.25 Thousand | -191.48 Thousand | -12.14 Thousand |
| Common Stock Issuance | 241.00 | 21.23 Thousand | 15.08 Million | 3.66 Million | 1.95 Million | -12.14 Thousand |
| Other Financing Activities | -79.99 Thousand | -40.8 Thousand | 21.38 Million | 400.25 Thousand | 191.48 Thousand | -12.14 Thousand |
| Accounts receivables | -2.04 Million | 680.34 Thousand | -825.43 Thousand | -1.01 Million | -58.64 Thousand | 403.58 Thousand |
| Accounts payables | 1.24 Million | -10.72 Thousand | 3716.00 | 28.51 Thousand | -16.23 Thousand | 247.43 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | - | - | - | - | - | -247.43 Thousand |
| Cash at beginning of period | 9.25 Million | 14.6 Million | 1.84 Million | 1.1 Million | 1.24 Million | 2.22 Million |
| Cash at end of period | 3.38 Million | 9.25 Million | 14.6 Million | 1.84 Million | 1.1 Million | 1.24 Million |
| Capital Expenditure | -2226.00 | -17.63 Thousand | -14.4 Thousand | -5347.00 | - | -3188.00 |
| Effect of forex changes on cash | 31.02 Thousand | 80.42 Thousand | -187.00 | -1411.00 | -2746.00 | 14.39 Thousand |
| Net cash flow / Change in cash | -5.87 Million | -5.35 Million | 12.76 Million | 740.29 Thousand | -132.79 Thousand | -988.28 Thousand |
| Free Cash Flow | -5.12 Million | -5.3 Million | -4.41 Million | -2.92 Million | -2.08 Million | -990.53 Thousand |
| Breakdown | 2024 Q4 | 2024 FY | 2024 Q2 | 2023 Q4 | 2023 FY | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -3.37 Million | -4.5 Million | -1.12 Million | -3.33 Million | -6.24 Million | -2.91 Million |
| Depreciation & Amortization | 43.2 Thousand | 86.14 Thousand | 42.94 Thousand | 44.37 Thousand | 73.36 Thousand | 28.99 Thousand |
| Deferred income taxes | - | - | - | -896.95 Thousand | 313.78 Thousand | - |
| Stock-based compensation | 39.73 Thousand | 85.99 Thousand | 46.26 Thousand | 127.86 Thousand | 209.09 Thousand | 81.23 Thousand |
| Change in working capital | -2.04 Million | -796.01 Thousand | - | 680.34 Thousand | 669.61 Thousand | - |
| Other non-cash items | 3.75 Million | 1.05 Million | -2.37 Million | 1.02 Million | -313.11 Thousand | 4562.00 |
| Investing Cash Flow | -2226.00 | -2226.00 | 9.25 Million | -3877.00 | -58.42 Thousand | -54.54 Thousand |
| Investments in PPE | -2226.00 | -2226.00 | - | -3877.00 | -17.63 Thousand | -13.75 Thousand |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | -40.79 Thousand | -40.79 Thousand |
| Financing Cash Flow | -687.43 Thousand | -772.98 Thousand | -85.55 Thousand | -70.14 Thousand | -84.21 Thousand | -14.07 Thousand |
| Debt repayment | -633 Thousand | -633 Thousand | -39.75 Thousand | - | -64.64 Thousand | -25.85 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | -1.00 | - | - |
| Common Stock Issuance | 172.00 | 241.00 | 69.00 | -1.00 | 21.23 Thousand | 21.23 Thousand |
| Other Financing Activities | -687.43 Thousand | -79.99 Thousand | -45.79 Thousand | -70.14 Thousand | -40.8 Thousand | 11.78 Thousand |
| Accounts receivables | -2.04 Million | -2.04 Million | - | 680.34 Thousand | 680.34 Thousand | - |
| Accounts payables | - | 1.24 Million | - | - | -10.72 Thousand | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | - | - | - | - | - | - |
| Cash at beginning of period | 5.65 Million | 9.25 Million | 9.25 Million | 11.67 Million | 14.6 Million | 14.6 Million |
| Cash at end of period | 3.38 Million | 3.38 Million | 5.65 Million | 9.25 Million | 9.25 Million | 11.67 Million |
| Capital Expenditure | -2226.00 | -2226.00 | - | -3877.00 | -17.63 Thousand | -13.75 Thousand |
| Effect of forex changes on cash | 2613.00 | 31.02 Thousand | 28.4 Thousand | 4129.00 | 80.42 Thousand | 76.29 Thousand |
| Net cash flow / Change in cash | -2.27 Million | -5.87 Million | -3.59 Million | -2.42 Million | -5.35 Million | -2.92 Million |
| Free Cash Flow | -1.58 Million | -5.12 Million | -3.54 Million | -2.35 Million | -5.3 Million | -2.95 Million |
300969
LREN3
JACO
BIOQ
MMNNF
BNDSF